The product is Beyfortus (nirsevimab-alip), for which the FDA granted approval in July to its sponsors, Sanofi and AstraZeneca. Pediatrician offices and hospitals have reported problems accessing the antibody, partly because of a cloudy reimbursement model for doses that cost about $500 each.
The other holdup is demand outpacing supply.
“Despite an aggressive supply plan built to outperform past pediatric vaccine launches, demand for this product, especially for the 100 milligram doses used primarily for babies born before the RSV season, has been higher than anticipated,” Sanofi said in a statement.
The CDC’s Vaccines for Children program and Sanofi have temporarily put some orders on hold, according to the American Academy of Pediatrics.
The CDC plans to reopen ordering in a limited supply before the week of Oct. 23, with priority going to buyers that have not ordered yet and those requesting a small quantity, the AAP said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
